Genmab A/S/DKr GMAB
07:00
09:00
11:00
12:55
14:55
1D1W1MYTD1Y5YMAX
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on the development and commercialization of antibody therapeutics for the treatment of cancer. The company is known for its proprietary antibody technologies, such as the DuoBody® and HexaBody® platforms, which enhance the efficacy and potency of treatments. Genmab's key products include DARZALEX® (daratumumab), a monoclonal antibody used in the treatment of multiple myeloma, which is marketed in collaboration with Janssen Biotech. Founded in 1999, Genmab operates a global network of offices and research facilities, including significant operations in the United States and the Netherlands. The company's strategic positioning is bolstered by its robust pipeline of investigational drugs and strategic partnerships with pharmaceutical leaders.
Ticker
DKr GMAB
Sector
Primary listing
CSE
Employees
3,088
Headquarters
Copenhagen, Denmark
Website
Genmab A/S Metrics
BasicAdvanced
kr 117bn
22.07
kr 86.11
0.69
-
Price and volume
Market cap
kr 117bn
Beta
0.69
52-week high
kr 2,257.00
52-week low
kr 1,512.00
Average daily volume
128k
Financial strength
Current ratio
2.184
Quick ratio
2.166
Long term debt to equity
89.018
Total debt to equity
94.175
Interest coverage (TTM)
7.66%
Profitability
EBITDA (TTM)
8,736.198
Gross margin (TTM)
93.31%
Net profit margin (TTM)
21.05%
Operating margin (TTM)
32.99%
Effective tax rate (TTM)
20.60%
Revenue per employee (TTM)
kr 8,276,390
Management effectiveness
Return on assets (TTM)
8.48%
Return on equity (TTM)
14.96%
Valuation
Price to earnings (TTM)
22.071
Price to revenue (TTM)
4.598
Price to book
20.57
Price to tangible book (TTM)
-32.28
Price to free cash flow (TTM)
20.57
Free cash flow yield (TTM)
4.86%
Free cash flow per share (TTM)
92.393
Growth
Revenue change (TTM)
20.66%
Earnings per share change (TTM)
-25.81%
3-year revenue growth (CAGR)
18.44%
10-year revenue growth (CAGR)
35.68%
3-year earnings per share growth (CAGR)
2.56%
10-year earnings per share growth (CAGR)
25.51%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.